BioNTech SE is a German biotechnology firm headquartered in Mainz, which develops and manufactures active immunotherapies for patient-specific illness therapy. It creates drug candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, vaccines against infectious diseases, and protein replacement therapies for rare diseases, as well as engineered cell therapy, novel antibodies, and small molecule immunomodulators as cancer treatment options. In 2008, Uur Ahin, Zlem Türeci, and Christoph Huber created BioNTech. The business's efforts revolve around the research and manufacture of technology and pharmaceuticals for personalized cancer immunotherapy. The company has over 20 product candidates in development, eight in nine current clinical trials, and has treated over 250 patients with 17 different tumour types. With Pfizer and Fosun, the company is working on “Project Lightspeed” a project to create a revolutionary mRNA technology for a COVID-19 vaccine. On May 28, 2021, Pfizer and BioNTech received the first European Union approval for the COVID-19 vaccine in adolescents. BioNTech's Unique Selling Point or USP lies in its technology, which allows it to combine modes of action in a coordinated manner to cure cancer more effectively than currently available medications. Because of its synergistic platform and manufacturing capabilities, the company is at the forefront of the paradigm shift toward customized immunotherapies. BioNTech's vision statement reads, "We aspire to individualize cancer medicine".
Political |
Economic |
|---|---|
|
|
Social |
Technological |
|
|
Legal |
ENVIRONMENTAL |
|
|
The detailed PESTLE analysis for Biontech Se is presented below:
WHO’s Covax program to ensure availability of vaccines across the world: Covid-19 has wreaked havoc across the world. There is a need to vaccinate the populations across the world. However only few of the developed and developing countries have been able to either develop or procure the vaccines. For instance, USA, Europe, Russia, China and India are able to vaccinate the populations at an early stage. In order to help the vaccines reach the poorest nations Covax program has been started. It has reached 100 countries in 42 days. This was possible because of the donations from USA ($2 billion), EU (EUR 400 million) and many other countries. Support to the program was US president Joe Biden’s first move after taking charge. Looking at the multiple variants across countries and the different timings of rise in covid cases Covax is one of the most significant steps to eradicate the pandemic. Since this program has procured vaccines from BioNTech it increases the demand for vaccines. As most of the economies in the world may not be able to procure the vaccines without any aid.
Vaccine diplomacy has become a new way of international relations: The entire world is affected by the Covid-19 outbreak. According to official measures, as of February 2021, over 110 million people are affected by the virus, and more than 2 million people died due to the pandemic. Hence, development of vaccines became every crucial for countries to curb skyrocketing infection rates. Countries such as United States, Israel, United Arab Emirates, United Kingdom, and India have started to develop and roll out vaccine distribution. The countries which started to develop vaccines have engaged in “vaccine diplomacy” in order to provide vaccines to regions which did not have access to emerging vaccine candidates. European Union is also planning to donate vaccines to African healthcare workers. BioNTech needs to increase its production of vaccines if the country is planning to engage in “vaccine diplomacy”.
This section is available only in the 'Complete Report' on purchase
This section is available only in the 'Complete Report' on purchase
This section is available only in the 'Complete Report' on purchase
This section is available only in the 'Complete Report' on purchase
Climate change may accelerate the occurrence of diseases: Climate change has significantly impacted the entire ecosystem. According to WHO, it is expected that approximately 2,50,000 additional deaths per year will occur between the years 2030 and 2050 due to malnutrition, malaria, diarrhea and heat stress. Organizations and firms have taken steps to address the issue of climate change by pledging to achieve net-zero emission in the next few decades. BioNTech aims to be climate neutral by 2030. However, the carbon emission in 2020 was a little bit higher than previous year, accounting to 6,179 metric tons from 5,801 metric tons in 2019. In 2021, the company plans to use renewable resources to generate approximately 92% of its total energy.
Delivery Within * 1 Hour
